Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles

  • News Brief

    FDA asked Bayer Pharmaceuticals Corp. to suspend marketing of Trasylol®, used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study suggesting an increased risk for death.
  • ASHP again pushes medication safety changes

    Spurred by a medication error involving dangerous doses of heparin administered to the newborn children of actor Dennis Quaid, the American Society of Health-System Pharmacists (ASHP) reiterated calls for systemic changes to help reduce medication errors.
  • Reducing medication discrepancies

    Using a multidisciplinary medication reconciliation process can reduce the number of medication discrepancies that occur during admission and discharge.
  • Medication reconciliation improved, adverse events decreased

    Research conducted by Temple University Hospital and Temple University School of Pharmacy has found that having a pharmacist make rounds with a medicine team improves the accuracy of medication reconciliation and decreases adverse events due to medication error.
  • Full December 29, 2007 Issue in PDF

  • Use of Proton Pump Inhibitors and Other Acid Suppressive Medications in Newly Admitted Nursing Facility Patients

    Many nursing home patients are admitted with prescriptions for proton pump inhibitors or H2-receptor antagonists without any obvious indication.
  • Clinical Briefs by Louis Kuritzky, MD

    Incidentalomas:It's All In Your Head, Skin Cancer Screening: Our Patients Want It!, and Bell's Palsy: Steroids, Acyclovir, Both, or Neither?
  • Sorafenib Tablets(Nexavar®)

    Sorafenib has been approved by the FDA forthe treatment of inoperable hepatocellular cancer. It is an oral multikinase inhibitor that was previously approved for advanced renal cell carcinoma. It is manufactured by Bayer HealthCare AG in Germany and marketed by Bayer Pharmaceuticals Corporation as Nexavar.
  • Diagnosing Early Pancreatic Cancer

    Although pancreatic cancer growth is considered rapid, early recognition of resectable disease remains the best chance for long-term survival. It is possible that an early sign of evolving pancreatic neoplasm is glucose intolerance. In a series of 30 pancreatic cancer patients evaluated at the Mayo Clinic, CT scans obtained 6 months or more before the diagnosis revealed potentially resectable lesions in some, and this was notably true for those who had CT scans and new-onset diabetes several months before the diagnosis of pancreatic cancer. Thus, physicians evaluating adults with newly diagnosed diabetes should consider the possibility that the glucose intolerance is an accompaniment of early pancreatic neoplasia.
  • Intravenous Bisphosphonate and Facial Bones

    IV bisphosphonate treatment is associated with an increased risk of inflammation in the bones of the jaw and face.